|Day's Range||2.25 - 2.37|
|52 Week Range||0.13 - 4.74|
|PE Ratio (TTM)||-1.93|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) offered a key glimpse into its advanced muscle invasive bladder cancer (MIBC) Phase 2a trial at the American Society of Clinical Oncology conference over the weekend. In reaction, Rodman & Renshaw Joseph Pantginis sees beneficial opportunity for bladder cancer patients and is bullish on the firm's pipeline drug, reiterating a Buy rating on shares of RNN with a $19.50 price target, which represents a 391% increase from current levels.
The Rockville, Maryland-based company said it had a loss of 9 cents per share. Losses, adjusted for non-recurring costs, were 2 cents per share. The company's shares closed at 40 cents. A year ago, they ...
These ten penny stocks trading on U.S. public exchanges could gain substantial ground in April 2017 and the coming months.